China Approves First Domestic CAR-T Therapy

Fosun Kite's Axicabtagene Ciloleucel recently received marketing authorization by NMPA, becoming the first CAR-T therapy approved in China. The Chinese CAR-T industry is thus eyeing a promising future, but the road to market success is challenging.
by Grace Wang Jul 12, 2021

Axicabtagene Ciloleucel Injection (brand name: Yescarta) was recently granted marketing approval by China National Medical Products Administration (NMPA)1, marking the first approved chimeric antigen receptor T-cell (CAR-T) therapy in China and the sixth globally.

Grace Wang
ChemLinked Regulatory Analyst
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact